SEC Form 10-Q Summary
Filing identity: The supplied filing identifies the registrant as Nile Therapeutics, Inc., not Capricor Therapeutics, Inc. Investors should verify that this is the intended filing. The report covers the quarter and nine months ended September 30, 2012; the signature date is June 21, 2013.
Business Context and Reporting Period
Nile was a development-stage biopharmaceutical company focused on cardiovascular and renal diseases. Its principal candidates were cenderitide, in development for heart failure, and CU-NP, a preclinical natriuretic peptide. The company had no product sales and relied on equity, debt, grants, and collaboration funding.
The Medtronic-supported Phase 1 cenderitide trial was completed in the first quarter of 2012. Further development of both candidates was on hold pending financing or a strategic transaction.
Financial Highlights
| Metric | Three months ended September 30 | Nine months ended September 30 | Comparable prior period |
|---|---|---|---|
| Total income | $0 | $195,500 | $813,000 and $2.03 million, respectively |
| Research and development expense | $179,142 | $976,945 | $1.47 million and $2.80 million, respectively |
| General and administrative expense | $397,170 | $1.34 million | $499,273 and $1.60 million, respectively |
| Net loss | $566,232 | $1.69 million | $1.14 million and $3.22 million, respectively |
| Loss per share | $0.01 | $0.04 | $0.03 and $0.09, respectively |
| Cash used in operating activities | Not separately provided | $1.95 million | $3.08 million |
At September 30, 2012, cash and cash equivalents were $282,507 versus $1.04 million at December 31, 2011. Working capital was approximately $151,000, total liabilities were $467,993, and stockholders’ equity was only $27,232. The company reported a $46.5 million accumulated deficit since inception.
The company had no traditional interest-bearing debt outstanding at September 30, 2012, but reported a $180,850 warrant liability. In April 2012, it raised gross proceeds of $1.34 million through the sale of 3.35 million shares and warrants; net proceeds were approximately $1.19 million.
Material Changes Versus the Prior Comparable Period
- Quarterly net loss declined to $566,232 from $1.14 million, primarily because research and development activity declined after completion of the Medtronic Phase 1 trial.
- Nine-month net loss declined to $1.69 million from $3.22 million, and operating cash usage declined to $1.95 million from $3.08 million.
- Quarterly R&D expense fell approximately 88% year over year, while nine-month R&D expense fell approximately 65%.
- Collaboration income declined to zero for the quarter and $195,500 for the nine-month period, compared with $813,000 and $1.16 million, respectively. The Medtronic agreement expired in February 2012 after final reimbursement.
- Cash declined by approximately $757,000 during the first nine months, despite $1.19 million of financing proceeds.
- Shares outstanding increased to 43.1 million from 39.7 million at December 31, 2011, reflecting the April 2012 financing and resulting dilution.
Outlook, Risks, Contingencies, and Unusual Items
Management stated that available cash, together with the net proceeds of a March 2013 secured convertible-note financing, was sufficient only for minimal operating expenses through the end of the second quarter of 2013. The financial statements disclosed substantial doubt about the company’s ability to continue as a going concern.
The March 2013 financing generated an aggregate purchase price of $382,500 for $450,000 of secured convertible notes. The notes mature March 15, 2014, carry no stated interest, are secured by a blanket lien, and may require repayment at 175% of principal upon certain changes of control.
A Phase 2 cenderitide trial was estimated to cost approximately $15 million to $20 million and take about 30 months. No financing or collaboration commitment sufficient to fund the trial had been obtained, and management indicated that failure to raise capital could result in cessation and wind-down of operations.
The company was not in compliance with several provisions of both Mayo license agreements, including annual maintenance payments and active development requirements. It owed Mayo approximately $193,400 in aggregate and was negotiating amendments. Failure to reach an agreement could result in loss of the rights to cenderitide and CU-NP.
The April 2012 warrants contained anti-dilution provisions and were classified as a liability. Their fair value declined from approximately $611,896 at issuance to $180,850 at September 30, 2012, producing approximately $431,000 of noncash other income.
Other significant risks included regulatory approval, clinical-trial execution, intellectual-property protection, dependence on financing or partners, potential equity dilution, restrictive debt terms, and the absence of product revenue. Management reported that disclosure controls and procedures were effective and that there were no material pending legal proceedings.
Most Important Facts to Verify
- Confirm the registrant: the supplied document is for Nile Therapeutics, Inc., despite the request naming Capricor Therapeutics, Inc.
- Verify the going-concern conclusion and whether subsequent financing provided liquidity beyond the second quarter of 2013.
- Review the terms and dilution implications of the March 2013 secured convertible notes and the 10.8 million outstanding warrants.
- Confirm whether Mayo amended or terminated the cenderitide and CU-NP license agreements and whether the company retained those rights.
- Assess whether cenderitide or CU-NP development resumed and whether a partner or strategic transaction was completed.
- Reconcile the filing’s reporting period with its June 2013 signature date and review subsequent filings for updated financial information.